Berliner Boersenzeitung - Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

EUR -
AED 4.331285
AFN 75.468553
ALL 95.455853
AMD 435.133136
ANG 2.110613
AOA 1082.496254
ARS 1649.279971
AUD 1.625795
AWG 2.125489
AZN 2.009303
BAM 1.960362
BBD 2.374715
BDT 144.673819
BGN 1.967008
BHD 0.445031
BIF 3508.088307
BMD 1.179189
BND 1.49518
BOB 8.147963
BRL 5.795828
BSD 1.179039
BTN 111.34021
BWP 15.830843
BYN 3.332255
BYR 23112.111202
BZD 2.371308
CAD 1.612011
CDF 2670.864298
CHF 0.916177
CLF 0.026704
CLP 1051.00014
CNY 8.019372
CNH 8.014083
COP 4422.526062
CRC 542.013173
CUC 1.179189
CUP 31.248518
CVE 110.903223
CZK 24.334582
DJF 209.565995
DKK 7.476537
DOP 69.985351
DZD 155.960046
EGP 62.195977
ERN 17.68784
ETB 185.491052
FJD 2.574218
FKP 0.866493
GBP 0.864889
GEL 3.154379
GGP 0.866493
GHS 13.313508
GIP 0.866493
GMD 86.674958
GNF 10353.282886
GTQ 9.002953
GYD 246.714182
HKD 9.235117
HNL 31.390478
HRK 7.538916
HTG 154.379289
HUF 353.981307
IDR 20491.303919
ILS 3.421187
IMP 0.866493
INR 111.345548
IQD 1544.738045
IRR 1546506.829043
ISK 143.873347
JEP 0.866493
JMD 185.842514
JOD 0.836092
JPY 184.734208
KES 152.328133
KGS 103.085327
KHR 4728.549695
KMF 492.90156
KPW 1061.212561
KRW 1723.880942
KWD 0.36279
KYD 0.982687
KZT 544.929701
LAK 25889.102525
LBP 105596.406437
LKR 379.599647
LRD 216.385693
LSL 19.327363
LTL 3.48184
LVL 0.71328
LYD 7.458419
MAD 10.754655
MDL 20.163928
MGA 4911.324039
MKD 61.616155
MMK 2475.833955
MNT 4220.203791
MOP 9.507427
MRU 47.102764
MUR 55.210091
MVR 18.163925
MWK 2054.148249
MXN 20.255648
MYR 4.623647
MZN 75.362436
NAD 19.327358
NGN 1609.593864
NIO 43.293982
NOK 10.859513
NPR 178.160636
NZD 1.976185
OMR 0.453919
PAB 1.179144
PEN 4.04993
PGK 5.129916
PHP 71.358689
PKR 328.581553
PLN 4.239717
PYG 7202.120307
QAR 4.29269
RON 5.21945
RSD 117.297547
RUB 87.543025
RWF 1722.206041
SAR 4.459737
SBD 9.456429
SCR 16.459646
SDG 708.107537
SEK 10.86706
SGD 1.494391
SHP 0.880384
SLE 29.067455
SLL 24727.006491
SOS 673.91103
SRD 44.100547
STD 24406.83871
STN 24.939855
SVC 10.317092
SYP 130.352242
SZL 19.303765
THB 37.973479
TJS 11.001504
TMT 4.127163
TND 3.379601
TOP 2.839205
TRY 53.475102
TTD 7.990886
TWD 36.927538
TZS 3063.998569
UAH 51.791223
UGX 4417.888438
USD 1.179189
UYU 47.025255
UZS 14309.46312
VES 588.693738
VND 31022.113342
VUV 139.175172
WST 3.188636
XAF 657.487181
XAG 0.014668
XAU 0.00025
XCD 3.186819
XCG 2.124956
XDR 0.82014
XOF 657.402298
XPF 119.331742
YER 281.384102
ZAR 19.315951
ZMK 10614.123377
ZMW 22.449247
ZWL 379.698489
  • RBGPF

    0.0000

    63.18

    0%

  • JRI

    0.0000

    13.15

    0%

  • CMSD

    0.1140

    23.534

    +0.48%

  • BCC

    -2.0900

    70.67

    -2.96%

  • RIO

    2.2700

    105.38

    +2.15%

  • RYCEF

    -1.0800

    16.37

    -6.6%

  • RELX

    0.0759

    33.58

    +0.23%

  • CMSC

    0.1400

    23.11

    +0.61%

  • VOD

    0.5100

    16.2

    +3.15%

  • BCE

    -0.4300

    24.14

    -1.78%

  • GSK

    -0.0900

    50.41

    -0.18%

  • NGG

    0.9800

    86.89

    +1.13%

  • BTI

    0.2000

    58.28

    +0.34%

  • AZN

    0.3300

    182.85

    +0.18%

  • BP

    -0.4700

    43.34

    -1.08%

Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives
Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

  • Joint venture executed combining Wellgistics Hub and KareRx Hub technology and operations

  • Integrated platform accelerates pharmaceutical access, fulfillment, and commercialization

  • Combined ecosystem provides potential reach to an estimated 200,000+ patient lives across pharmaceutical and provider networks

Text size:

TAMPA, FL / ACCESS Newswire / April 14, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced the execution of a definitive joint venture agreement with Kare PharmTech's wholly owned subsidiary, Kare Rx Hub, LLC ("KareRx"), an artificial intelligence (AI)-driven digital hub supporting retail pharmacy, telemedicine, and specialty pharmaceutical programs.

The execution of the joint venture formalizes the previously announced non-binding letter of intent and represents a significant milestone in aligning both organizations' technology platforms and operational teams into a unified ecosystem designed to accelerate patient access and improve the efficiency of pharmaceutical commercialization. By integrating the Wellgistics Hub technology stack including proprietary platforms EinsteinRx™ and HubRx AI™ with KareRx's digital hub, the combined platform is positioned to streamline the prescription journey from intake through fulfillment.

Prashant Patel, Chief Executive Officer of Wellgistics Health, commented, "This joint venture reflects our continued focus on building an integrated, technology-enabled platform to improve coordination across the prescription journey and support patient access to therapies. By combining KareRx's provider connectivity and digital engagement capabilities with our infrastructure, we believe this collaboration enhances operational efficiency and supports manufacturers and other healthcare stakeholders in navigating access pathways more effectively."

The joint venture aligns clinical, operational, and commercial teams across both organizations, enabling more seamless coordination between providers, pharmacies, and patients. Through this integration, the platform enhances key capabilities including eligibility and benefits verification, prior authorization workflows, prescription routing, and direct-to-patient fulfillment. The combined ecosystem includes a growing national footprint of independent pharmacies, provider networks, and telehealth channels, with the ability to reach more than 200,000 patient lives based on third-party internal estimates.

Mital Panera, Founder and Chief Executive Officer of KareRx, added, "KareRx was developed to connect providers, pharmacies, and patients through technology-driven solutions. This joint venture allows us to extend those capabilities by leveraging Wellgistics' technology stack, pharma expertise, and operational infrastructure. We believe the combined platform will support improved connectivity across stakeholders and facilitate access to therapies across participating networks."

The collaboration further strengthens direct-to-patient (DTP) and decentralized care models, providing pharmaceutical manufacturers with a comprehensive platform that integrates access, affordability, and fulfillment into a single solution. Leveraging AI-driven insights and a fully integrated operational backbone, the joint venture is designed to reduce barriers to therapy initiation, improve adherence, and deliver enhanced visibility into patient access and program performance.

The joint venture remains subject to customary implementation steps, and there can be no assurance regarding the timing or extent of operational integration or the realization of anticipated benefits. Additional details regarding the joint venture agreement will be provided in a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission.

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx into its patented blockchain-enabled smart contracts platform PharmacyChain to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.

About Kare PharmTech, LLC

Kare Rx Hub is an artificial intelligence (AI)-based digital hub for retail pharmacies, telemedicine portal, and specialty pharmaceutical 'lite' branded products with over 500 physician-provider relationships, 200 independent pharmacy relationships that market unique specialty pharmaceutical 'lite' products. Kare Rx Hub is owned by Kare Pharmtech, LLC, a company controlled by Dr. Kiran Patel. Dr. Patel founded Medicaid provider WellCare in 1992 and sold it in 2002 for $200 million. In 2007, Dr. Patel founded America's 1st Choice Holdings and acquired Freedom Health and Optimum Holdings. In 2017, he sold America's 1st Choice Holdings to Anthem, Inc. Dr. Patel is a noted philanthropist and was named Floridian of the Year by Florida Trend Magazine.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.

Wellgistics Media & Investor Contact
Media: [email protected]
Investor Relations: [email protected]

SOURCE: Wellgistics Health, Inc.



View the original press release on ACCESS Newswire

(A.Lehmann--BBZ)